Kura Oncology (KURA) Stock Forecast & Price Target

Compare

772 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KURA Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Kura

Oncology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KURA Stock 12 Month Forecast

Average Price Target

$29.00

▲(183.76% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $29.00 with a high forecast of $40.00 and a low forecast of $16.00. The average price target represents a 183.76% change from the last price of $10.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","32":"$32","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14,23,32,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.44,13.636923076923077,15.833846153846153,18.03076923076923,20.22769230769231,22.424615384615386,24.621538461538464,26.81846153846154,29.01538461538462,31.212307692307697,33.409230769230774,35.60615384615385,37.80307692307692,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.44,12.79076923076923,14.141538461538461,15.492307692307692,16.84307692307692,18.193846153846152,19.544615384615383,20.895384615384614,22.246153846153845,23.596923076923076,24.947692307692307,26.298461538461538,27.64923076923077,{"y":29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.44,11.79076923076923,12.141538461538461,12.492307692307692,12.843076923076923,13.193846153846154,13.544615384615383,13.895384615384614,14.246153846153845,14.596923076923076,14.947692307692307,15.298461538461538,15.649230769230769,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$29.00

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Roger Song

Jefferies

$28

Buy

173.97%

Upside

Reiterated

12/10/25

Kura Oncology (KURA) Gets a Buy from Jefferies

Etzer Darout

Barclays

$28

Buy

173.97%

Upside

Reiterated

12/09/25

Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)

Jason Zemansky

Bank of America Securities

$30

Buy

193.54%

Upside

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA) and Autolus Therapeutics (NASDAQ: AUTL)

Charles Zhu

LifeSci Capital

$28

Buy

173.97%

Upside

Reiterated

12/09/25

Kura Oncology's Promising Clinical Data and Strategic Partnerships Justify Buy RatingYesterday in two oral presentaons a t ASH and during an investor webcast, KURA and discussants outlined Ph 1a/b 600mg zi o+ven/aza results from US trial KOMET-007. The update included a ﬁrst look at the triplet in newly diagnosed (ND; "1L") NPM1m AML (SLIDES) and updated r/r NPM1m and KMT2Ar data (SLIDES). We believe these data connue t o posion zi omenib compev ely in combinaon, while main taining a potenal lead in 1L giv en funding from the 2024 Kyowa Kirin deal and clinical progress, having inia ted pivotal Phase 3 KOMET-017 trial in September 2025 (with MRD- CR primary endpoint for IC combo opening a path to accelerated approval).

Joseph Pantginis

H.C. Wainwright

$40

Buy

291.39%

Upside

Reiterated

12/09/25

Positive Outlook for Kura Oncology Driven by Promising Clinical Trials and Strategic Advancements

Justin Zelin

BTIG

―

Hold

―

Reiterated

12/09/25

BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)

Robert Driscoll

Wedbush

$38

Buy

271.82%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Phreesia (PHR), Wave Life Sciences (WVE)Reiterate OUTPERFORM and our $38 PT.

David Dai

UBS

$14→$16

Buy

56.56%

Upside

Reiterated

11/14/25

UBS Sticks to Its Buy Rating for Kura Oncology (KURA)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/13/25

TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

10/20/25

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Kura Oncology (NASDAQ: KURA) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Reni Benjamin

Citizens JMP

$24

Buy

134.83%

Upside

Reiterated

09/30/25

Kura Oncology (KURA) Gets a Buy from Citizens JMPCitizens JMP analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

Bradley Canino

Guggenheim

$7.95

Hold

-22.21%

Downside

Initiated

09/03/25

Kura Oncology initiated with a Neutral at GuggenheimKura Oncology initiated with a Neutral at Guggenheim

Mara Goldstein

Mizuho Securities

$30

Buy

193.54%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

$10→$8

Hold

-21.72%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Roger Song

Jefferies

$28

Buy

173.97%

Upside

Reiterated

12/10/25

Kura Oncology (KURA) Gets a Buy from Jefferies

Etzer Darout

Barclays

$28

Buy

173.97%

Upside

Reiterated

12/09/25

Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)

Jason Zemansky

Bank of America Securities

$30

Buy

193.54%

Upside

Reiterated

12/09/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA) and Autolus Therapeutics (NASDAQ: AUTL)

Charles Zhu

LifeSci Capital

$28

Buy

173.97%

Upside

Reiterated

12/09/25

Joseph Pantginis

H.C. Wainwright

$40

Buy

291.39%

Upside

Reiterated

12/09/25

Positive Outlook for Kura Oncology Driven by Promising Clinical Trials and Strategic Advancements

Justin Zelin

BTIG

―

Hold

―

Reiterated

12/09/25

BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)

Robert Driscoll

Wedbush

$38

Buy

271.82%

Upside

Reiterated

12/09/25

Analysts' Top Healthcare Picks: Phreesia (PHR), Wave Life Sciences (WVE)Reiterate OUTPERFORM and our $38 PT.

David Dai

UBS

$14→$16

Buy

56.56%

Upside

Reiterated

11/14/25

UBS Sticks to Its Buy Rating for Kura Oncology (KURA)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/13/25

TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

10/20/25

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (NYSE: BHC), Kura Oncology (NASDAQ: KURA) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Reni Benjamin

Citizens JMP

$24

Buy

134.83%

Upside

Reiterated

09/30/25

Kura Oncology (KURA) Gets a Buy from Citizens JMPCitizens JMP analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

Bradley Canino

Guggenheim

$7.95

Hold

-22.21%

Downside

Initiated

09/03/25

Kura Oncology initiated with a Neutral at GuggenheimKura Oncology initiated with a Neutral at Guggenheim

Mara Goldstein

Mizuho Securities

$30

Buy

193.54%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA), Eli Lilly & Co (NYSE: LLY) and Nkarta (NASDAQ: NKTX)

Li Watsek

Cantor Fitzgerald

―

Buy

―

Reiterated

06/26/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Kura Oncology (KURA)

George Farmer

Scotiabank

$10→$8

Hold

-21.72%

Downside

Reiterated

06/04/25

Scotiabank Sticks to Their Hold Rating for Kura Oncology (KURA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kura Oncology

1 Month

xxx

Success Rate

21/34 ratings generated profit

Average Return

+2.87%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.76% of your transactions generating a profit, with an average return of +2.87% per trade.

3 Months

xxx

Success Rate

25/43 ratings generated profit

Average Return

+10.92%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +10.92% per trade.

1 Year

Jason ZemanskyBank of America Securities

Success Rate

13/20 ratings generated profit

Average Return

+11.20%

reiterated a buy rating 7 days ago

Copying Jason Zemansky's trades and holding each position for 1 Year would result in 65.00% of your transactions generating a profit, with an average return of +11.20% per trade.

2 Years

xxx

Success Rate

13/21 ratings generated profit

Average Return

+4.44%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 61.90% of your transactions generating a profit, with an average return of +4.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KURA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KURA has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KURA average Analyst price target in the past 3 months is 29.00.

Each month's total comprises the sum of three months' worth of ratings.

KURA Financial Forecast

KURA Earnings Forecast

Next quarter’s earnings estimate for KURA is -$0.25 with a range of -$1.43 to $1.10. The previous quarter’s EPS was -$0.85. KURA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KURA has Performed in-line its overall industry.

KURA Sales Forecast

Next quarter’s sales forecast for KURA is $75.81M with a range of $652.00K to $176.95M. The previous quarter’s sales results were $20.75M. KURA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KURA has Performed in-line its overall industry.

KURA Stock Forecast FAQ

What is KURA’s average 12-month price target, according to analysts?

Based on analyst ratings, Kura Oncology’s 12-month average price target is 29.00.

What is KURA’s upside potential, based on the analysts’ average price target?

Kura Oncology has 183.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KURA a Buy, Sell or Hold?

Kura Oncology has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Kura Oncology’s price target?

The average price target for Kura Oncology is 29.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $16.00. The average price target represents 183.76% Increase from the current price of $10.22.

What do analysts say about Kura Oncology?

Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of KURA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Kura Oncology (KURA) Stock Forecast & Price Target

KURA Analyst Ratings

KURA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Kura Oncology

KURA Analyst Recommendation Trends

KURA Financial Forecast

KURA Earnings Forecast

KURA Sales Forecast

KURA Stock Forecast FAQ

Detailed List of Analyst Forecasts